INBS INTELLIGENT BIO SOLUTIONS INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1725430 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY57.2%
TTM net income YoY-11.4%
TTM EPS YoY74.6%
Revenue 3-yr CAGR27.6%
Net income 3-yr CAGR—
Margins
Gross margin50.9%
Operating margin-272.2%
Net margin-269.3%
FCF margin—
EBITDA margin-246.5%
Returns
ROE-216.1%
ROA-102.3%
ROIC (approx.)-534.9%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets46.0%
Debt / equity0.00x
Current ratio1.98x
Interest coverage-187.68x
Cash quality & payout
Operating cash flow / net income0.98x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.39M | $1.15M | $1.06M | $896,774 | $1.11M | $410,845 | $728,867 | $607,494 |
| Cost of revenue | $633,831 | $609,219 | $525,421 | $437,035 | $593,506 | $508,307 | $387,499 | $384,381 |
| Gross profit | $758,004 | $536,583 | $535,381 | $459,739 | $518,291 | $335,577 | $341,368 | $223,113 |
| SG&A expense | $2.58M | $2.99M | $2.46M | $2.34M | $2.71M | $2.72M | $2.41M | $1.81M |
| Operating income | -$2.68M | -$3.97M | -$2.95M | -$2.64M | -$3.00M | -$3.11M | -$2.56M | -$2.26M |
| Interest expense | $1,435 | $3,301 | $4,241 | $56,209 | $2,309 | $5,312 | $7,919 | $13,502 |
| Net income | -$2.66M | -$3.91M | -$2.86M | -$2.68M | -$2.98M | -$3.09M | -$2.54M | -$2.25M |
| EBITDA | -$2.39M | -$3.68M | -$2.66M | -$2.35M | -$2.70M | -$2.81M | -$2.26M | -$1.96M |
| EPS (basic) | -0.86 | — | -1.80 | -2.82 | -3.49 | — | -4.41 | -4.96 |
| EPS (diluted) | -0.86 | — | -1.80 | -2.82 | -3.49 | — | -4.41 | -4.96 |
| Weighted avg. shares (diluted) | 3.10M | — | 1.59M | 950,829 | 854,693 | — | 577,191 | 453,582 |
| Balance sheet | ||||||||
| Cash & equivalents | $5.93M | $3.99M | $6.86M | $740,371 | $1.66M | $1.02M | $2.81M | $2.24M |
| Receivables | $999,756 | $848,464 | $878,357 | $456,657 | $717,823 | $594,614 | $510,963 | $266,080 |
| Inventory | $478,048 | $418,577 | $597,469 | $590,246 | $628,177 | $635,215 | $683,488 | $701,280 |
| Current assets | $9.05M | $7.10M | $9.75M | $12.17M | $4.48M | $4.14M | $5.11M | $4.06M |
| PP&E, net | $278,000 | $294,399 | $312,276 | $321,741 | $271,745 | $251,325 | $546,458 | $537,225 |
| Intangibles | $2.60M | $2.80M | $3.00M | $3.27M | $3.47M | $3.79M | $3.80M | $3.90M |
| Total assets | $13.62M | $11.94M | $14.86M | $17.65M | $10.04M | $8.25M | $9.58M | $8.68M |
| Current liabilities | $4.58M | $4.93M | $4.61M | $5.13M | $5.06M | $5.35M | $4.56M | $4.40M |
| Total liabilities | $6.27M | $6.65M | $6.11M | $6.76M | $6.61M | $5.44M | $4.64M | $4.48M |
| Shareholders' equity | $7.58M | $5.51M | $8.96M | $11.09M | $3.62M | $3.00M | $5.11M | $4.37M |
| Shares outstanding | 3.32M | 2.91M | 2.00M | 1.24M | 9.10M | 732,327 | 6.79M | 4.81M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.75M | -$3.18M | -$4.33M | -$1.57M | -$2.85M | -$2.21M | -$2.76M | -$2.32M |
| Capital expenditure | — | $0 | -$12,902 | $68,232 | $70,401 | — | — | — |
| Free cash flow | — | -$3.18M | -$4.32M | -$1.64M | -$2.92M | — | — | — |
| Investing cash flow | — | $0 | $12,902 | -$28,074 | -$70,401 | -$208,517 | -$14,385 | — |
| Financing cash flow | $4.68M | $311,989 | $10.44M | $674,651 | $3.56M | $601,997 | $3.32M | $631,744 |
| Depreciation & amortization | $293,835 | $288,180 | $290,393 | $281,896 | $303,378 | $300,298 | $301,978 | $305,177 |
| Stock-based compensation | $98,368 | $97,429 | $12,204 | $61,575 | $12,000 | $12,000 | $0 | $12,000 |
Free plan shows the latest 8 periods; Pro shows all 29 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.